发明名称 |
Anti-RSPO2 antibodies |
摘要 |
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer. |
申请公布号 |
US9109025(B2) |
申请公布日期 |
2015.08.18 |
申请号 |
US201414318253 |
申请日期 |
2014.06.27 |
申请人 |
OncoMed Pharmaceuticals, Inc. |
发明人 |
Gurney Austin L.;Axelrod Fumiko Takada;Hoey Timothy Charles;Chartier-Courtaud Cecile |
分类号 |
A61K39/00;A61K39/395;C07K16/00;C07K16/18;C07K16/30;G01N33/574;A61K45/06;C07K16/28 |
主分类号 |
A61K39/00 |
代理机构 |
Sterne, Kessler, Goldstein & Fox, P.L.L.C. |
代理人 |
Sterne, Kessler, Goldstein & Fox, P.L.L.C. |
主权项 |
1. An isolated antibody that specifically binds human R-spondin 2 (RSPO2), which comprises:
(a) a heavy chain CDR1 comprising SSYAMS (SEQ ID NO:29), a heavy chain CDR2 comprising SISSGGSTYYPDSVKG (SEQ ID NO:30), and a heavy chain CDR3 comprising RGGDPGVYNGDYEDAMDY (SEQ ID NO:31); and (b) a light chain CDR1 comprising KASQDVSSAVA (SEQ ID NO:32), a light chain CDR2 comprising WASTRHT (SEQ ID NO:33), and a light chain CDR3 comprising QQHYSTP (SEQ ID NO:34). |
地址 |
Redwood City CA US |